Abstract Library

#590 Imaging of Metastatic-Recurrent Paragangliomas and Pheochromocytomas with Ga-68 DOTATATE PET/CT

Introduction: Approximately 73% of Pheochromocytomas(Pheo) and 93% of paragangliomas(PGL) express somatostatin receptors and Ga-68 DOTATATE PET/CT may have a role in metastatic PHEO/PGLs for determination of extent of disease.

Conference:

Presenting Author:

Authors: demirci e, ocak m, kabasakal l, yeyin n, asa s,

Keywords: Paragangliomas/Pheochromocytomas Gallium-68-DOTA-TATE,

#588 CORRELATION OF TUMOR ABSORBED DOSES OF 177LU-DOTA-TATE TREATMENT WITH PRE-THERAPEUTIC GA68 DOTA-TATE PET/CT UPTAKE IN NEUROENDOCRINE TUMORS

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) with Lu-177 aroused great interest. Estimation of actual radiation doses to tumors may help therapy planning.

Conference:

Presenting Author:

Authors: demirci e, kabasakal l, toklu t, ocak m, yeyin n,

Keywords: Tumor absorbed doses, PRRT, PET,

#517 Initial Experience of Biological Stability and Image Timing of Ga-68 DOTANOC in Somatostatin Receptor (sstr) Expressing Organ and Tumor

Introduction: Since Ga68 DOTATATE has a high affinity to only sstr2 but no affinity to sstr3 and sstr5, Ga68 DOTANOC has been suggested to be a better radioligand with higher affinity to sstr3 and sstr5 and high affinity to sstr2, as well.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Demirci E, Kabasakal L, Ocak M, Aygun A, Ozcan R,

Keywords: Octreotide PET,

#516 Evaluation of 68Ga-DOTA-TATE and 68Ga-DOTA-LAN PET/CT in Somatostatin Exopressing Organs and Tumors

Introduction: Octreotide derived radiolabelled peptides have been widely used for somatostatin receptor (sstr) imaging. Clinically used radiopeptides exclusively target sstr subtype 2. But radiolabeled Lanreotide has been claimed to bind sstr 2, 3 and 5.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kabasakal L, Demirci E, Ocak M, Aygun A, Decristoforo C,

Keywords: Octreotide PET,